New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...
BioNTech SE has taken another significant step in its strategic evolution from a vaccine-focused biotech to a diversified oncology leader. Recent clinical trial ...
The addition of pembrolizumab to neoadjuvant chemotherapy followed by single-agent adjuvant pembrolizumab improved long-term ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...
Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...
Data presented by Johnson & Johnson at the 2026 European Lung Cancer ConferencePARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) ...
Small cell lung cancer is one of the fastest growing and most dangerous types of cancer. It often spreads quickly through the body and is difficult to control. Many patients respond well to treatment ...
Nebraska meteorologist Kent Boughton revealed that he was diagnosed with an aggressive and fast-growing type of cancer. The ...
Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two drugs for the treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results